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Background: Bias in industry-sponsored trials is common and the interpretation of the results can be particularly
distorted in favour of the sponsor’s product. We investigated sponsors’ involvement in the conduct and reporting
of industry-sponsored trials.
Methods: We included all industry-sponsored trials published in The Lancet in 2008 and 2009 and corresponding
trial protocols provided by The Lancet. For each protocol and publication, we extracted information on trial conduct
and reporting.
Results: We identified 169 publications of randomised trials and included 69 (41%) that were industry-sponsored,
and 12 (7%) industry-funded but seemingly independently conducted as a subsample. Entry of data into the study
database was done independently by academic authors without the involvement of the sponsor or a contract
research organisation in one of the 69 trials. Two trials had independent data analysis and one independent
reporting of results. In 11 of the trials, there was a discrepancy between the information in the protocols and
papers concerning who analysed the data. In four of the 12 seemingly independent trials, the protocol described
sponsors’ involvement in writing the report while the published paper explicitly stated that the sponsor was not
involved.
Conclusions: The sponsors are usually involved in the analysis and reporting of results in industry-sponsored trials,
but their exact role is not always clear from the published papers. Journals should require more transparent
reporting of the sponsors’ role in crucial elements such as data processing, statistical analysis and writing of the
manuscript and should consider requiring access to trial protocols, independent data analysis and submission of
the raw data.
Keywords: Randomised trials, Industry sponsorship, Academic authors, Trial protocolsBackground
The drug and device industries have a major impact on
the research agenda. They funded 58% of US biomedical
research in 2007 [1], and 56% of trials published in high-
impact medical journals in 2005 and 2006 had industry
funding; for New England Journal of Medicine it was
78% [2]. The involvement of the company in industry-
sponsored trials varies from no involvement, besides the
free provision of drugs, to running the whole trial and
publishing the results without the involvement of aca-
demic authors.* Correspondence: al@cochrane.dk
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reproduction in any medium, provided the orIndustry-sponsored trials usually favour the company’s
product [3,4]. This may happen through biases in study
design, choice of comparators or selective reporting of
favourable outcomes [5,6]. Some journals therefore re-
quire that the involvement of the sponsor is stated in
the published article. JAMA goes further and requires
independent data analysis by academic authors [7].
Many industry-sponsored trials are coordinated by
seemingly independent steering committees. However, this
may not prevent sponsor influence, as academic authors
often have constraints on publication rights [8,9], the
sponsor often owns the data [9,10], ghost authorship is
common [11], and academic authors may have industry
ties [12].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





- 3 not reporting on trials
- 3 secondary analyses of trials*
- 5 published in 2010
169 trials identified
88 trials excluded
- 1 all authors employed by sponsor
- 85 not fully industry-funded
- 2 same protocols as other trials 
12 solely industry-funded trials with 
apparent independent data management 
and analysis included in subsample
69 industry trials included
Figure 1 Flow chart showing inclusion of trials.
*Secondary analysis refers to when the trial data were used in an
exploratory fashion. For example, the placebo group was analysed as
a separate cohort study to investigate heart rate as a predictor for
cardiovascular mortality in a trial of an anti-arrhythmic drug.
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of trials published in The Lancet in 2008 and 2009 [10].
We found that academic authors involved in industry-
sponsored trials may have limited access to the raw data,
although they all declared in The Lancet that they had
full access to the data. We report here on the sponsors’
influence on trial conduct and reporting of the results.
Methods
Sample
We identified all randomised clinical trials published in The
Lancet in 2008 and 2009 using the index term ‘randomized
controlled trial’ in PubMed. We excluded papers that were
not full trial reports (for example, letters and commentaries)
or were not part of the planned trials (for example, second-
ary analyses). We selected all industry-sponsored trials,
defined as trials fully funded by a drug or device company
and where the sponsor participated in data management or
analysis. Trials where part of trial conduct was outsourced to
a contract research organization (CRO) were also included.
Trials where all elements of trial conduct were managed by
independent academic authors (for example, by ’unrestricted’
grants) were analysed separately.
Since July 2002, The Lancet has required authors to sub-
mit protocols together with the trial report and we retrieved
copies of these protocols.
Information on trial conduct and reporting in protocols
and papers
One of us (AL) copied all information from protocols and
papers on data management, storage, analysis, and writing
of the protocol and manuscript into a pilot-tested data
sheet. Two observers (AL, LTK) independently categorized
these data into prespecified domains for protocols and
papers, and disagreements were resolved by discussion and
arbitration when needed by the third observer (PG). We
made a final categorization based on data from both proto-
cols and published papers and described discrepancies.
Results
We identified 209 papers in PubMed and excluded 40 that
were not primary reports of trials published in 2008 and
2009 (Figure 1). We excluded another 85 trials that were
not fully funded by the industry, two that had protocols
similar to other included trials, and one that had no inde-
pendent academic authors. Of the remaining 81 trials, we
included 69 industry-sponsored trials. The other 12 trials
were also fully industry-funded but appeared to have been
independently conducted and we therefore analysed them
separately.
For seven trials, the full protocols were missing: two were
not in The Lancet’s database, three were protocol synopses,
one was a copy of the information from www.clinicaltrials.
gov and one only consisted of amendments to the protocol.We received copies of five protocols from the academic
authors and the other two from the sponsors.
Data management
In 49 of the 69 trials (71%), review and verification of infor-
mation in case report forms (CRFs) were handled by the
sponsor or a CRO without involvement of academic authors
and only in two trials (3%) by academic authors independ-
ently (Table 1).
In 52 trials (75%), entry of data into the study database
was done by the sponsor or a CRO without involvement
of academic authors. In only two of these trials, it was
described how data were processed, that is, interpreted for
categorisation purposes, and in those two trials, all safety
data were processed by sponsor staff. In only one trial
(1%) was data entry performed independently by academic
authors. However, based only on information in the pub-
lished paper, it was not possible to tell who entered study
data in 50 (72%) of the trials. In 44 trials (64%), the data
were stored by the sponsor or a CRO and only in one trial
(1%) by academic authors. In one trial (1%), the protocol
suggested that academic authors stored the data whereas
the paper suggested that the sponsor stored it.
According to 38 trial protocols (55%), the sponsor had
access to accumulating data before study termination and
according to two (3%) the sponsor had access via member-
ship of the Data and Safety Monitoring Board. In 24 of
these 40 trials, the sponsor could stop the trial prematurely
Table 1 Data management and analysis in industry-sponsored trials based on information in protocols and
publications
(n = 69) CRF review and verification Data entry Data storage Data analysis
Sponsor 23 (33%) 32 (46%) 35 (51%) 29 (42%)
Sponsor and CRO 18 (26%) 8 (12%) 3 (4%) 6 (9%)
CRO 8 (12%) 12 (17%) 6 (9%) 5 (7%)
Sponsor/CRO and academic authors 10 (14%) 0 (0%) 0 (0%) 11 (16%)
Academic authors 2 (3%) 1 (1%) 1 (1%) 2 (3%)
Not described 8 (12%) 16 (23%) 23 (33%) 5 (7%)
Discrepancy between protocol and paper 0 (0%) 0 (0%) 1 (1%) 11 (16%)
Percentages do not always add up to 100 due to rounding.
Table 2 Sponsors’ influence on publication of results of
industry-sponsored trials based on information in
protocols and publications
(n = 69) Publication of results
Sponsor has co-authorship 56 (81%)
Sponsor needs to approve manuscript 3 (4%)
Sponsor needs to review or comment 5 (7%)
No influence 1 (1%)
Not described 1 (1%)
Discrepancy between protocol and paper 3 (4%)
Percentages do not add up to 100 due to rounding.
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all, in five additional trials it could also be stopped but no
criteria were specified, and in the remaining 11 trials it was
not described whether the sponsor could stop the trial
prematurely.
Data analysis
In 40 trials (58%), the data were analysed by the sponsor or
a CRO without involvement of academic authors and only
in two trials (3%) independently by academic authors. In 11
trials (16%) the sponsor or a CRO, and academic authors
analysed the data. However, in six of these trials, the spon-
sor or CRO biostatistician had the primary role and in five,
the role was not clear as many authors were listed. In one
of these five trials, the protocol named a sponsor-employed
study biostatistician who was not mentioned in the paper.
In an additional 11 trials (16%), there were discrepancies
between information in protocols and papers. In four, the
protocol described analysis by sponsor or CRO alone
whereas the published paper described analysis either by
academic authors alone or in collaboration with the spon-
sor. In five trials, there were discrepancies between infor-
mation in protocols and papers as to whether the sponsor
or a CRO did the analysis, and in two the protocol
described an independent analysis by academic authors
whereas the papers also described involvement of a CRO or
the sponsor. Based only on information in the published
paper, it was not possible to tell who analysed the data in
another 10 (14%) of the trials.
Publication of the results
In 24 of the 69 trials (35%), the sponsor or a hired CRO was
involved in coordinating writing of the manuscript, in 10
(14%) the sponsor was not involved and in 35 (51%) it was
not described. In 64 trials (93%), the sponsor had influence
over publication of the results through co-authorship or an
explicitly stated right to approve, review or comment on the
paper (Table 2). In three trials (4%), there were discrepancies
between information in protocols and papers: one protocol
described sponsor-employed co-authors without this beingstated in the paper; in one protocol the sponsor needed to
approve the manuscript, but the paper stated that the spon-
sor was not involved in writing of the report; and in one
protocol the sponsor needed to approve the manuscript, but
the paper stated that the report was written in consultation
with the sponsor.
Ten of the protocols (14%) referred to separate agree-
ments (for example, clinical trial agreements or publica-
tion agreements) concerning reporting of results or data
ownership and five other protocols (7%) stated that such
agreements might be issued, overriding statements con-
cerning reporting of results or data ownership in the
protocol. None of these agreements had been provided
to The Lancet. Finally, five protocols explicitly described
that the sponsor could publish the results without au-
thor approval, but this did not seem to have happened
(there were academic authors on all 69 papers).
Medical writing assistance from the sponsor or per-
sons hired by the sponsor was described in 37 of the 69
papers (54%), in seven papers (10%) it seemed no assist-
ance was provided and in 25 (36%) it was not described.
Sixty-eight of the 69 protocols (99%) seemed to have
been written by the sponsor, for example, by including
the company logo, and one protocol contained no infor-
mation indicating who had written it. In 19 protocols,
specific authors were named and 10 of these protocols
specified them as authors of the protocol. However, for
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tioned in the publications.
Independently conducted trials
In eight of the additional 12 trials that appeared to have
been conducted independently of the sponsor, the sponsor
nevertheless appeared to have written the protocol, could
stop the trial early, had issued confidentiality clauses or
had influence on writing of the manuscript (Table 3).
Discussion
Approximately half the trials published in The Lancet were
fully funded by the industry and most of these had industry
involvement in the conduct, analysis and reporting of the
results. The sponsor often entered, stored and owned the
data, which were rarely analysed independently by the aca-
demic authors. Even for the additional 12 trials that appeared
to have been conducted independently of the sponsor, the
sponsor could stop the trial prematurely in some cases,
issued confidentiality clauses, was involved in the reporting
of results or appeared to have written the protocol.
Our study describes sponsor involvement in the conduct
and reporting of industry-sponsored trials published in a
high-impact medical journal. Our access to trial protocols
gave us additional information on sponsor involvement not
possible to decipher from the published papers alone. A
study of cancer trials found that only 18% of the industry-
sponsored trials described the sponsors’ role and usually in
vague terms [13]. There are some limitations that should be
taken into account though. First, we restricted our sample to
trials published in a single journal, The Lancet, which may
limit generalisability. However, The Lancet’s access to proto-
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despite access to trial protocols, in many cases we could not
tell who entered, processed or stored data, and we did not
have copies of trial agreements and publication agreements.
We find it likely that tasks not described were handled by
the sponsor because the protocols in all except one case were
most likely written by the sponsor. It might therefore be
regarded as implicit that what had been left out would be
managed by the sponsor. The role of the sponsor may there-
fore be even more extensive than our results indicate.
Bias in industry-sponsored trials can be introduced at vari-
ous levels of data processing, from the information being
recorded on CRFs to the data appearing in the published
paper. In most cases, the sponsor or a hired CRO was in
charge of data entry and while it was rarely described, they
probably also processed the data for categorisation purposes.
Processing data is bias-prone. Important data are often
omitted from publications or are described in a way
favourable for the sponsor. For example, suicidality was
coded as ‘emotional lability’, ‘hospital admission’ or ‘lack of
effect’ in trials of selective serotonin reuptake inhibitors
(SSRIs) [14,15], myocardial infarctions on rofecoxib were
omitted in the VIGOR trial [16,17] and on rosiglitazone in
the RECORD trial [18,19]. As academic authors were
rarely involved in data entry, and as data analysis by aca-
demics often did not involve anything more than checking
the tabulated data in the clinical study report [10], such
practices will most likely not be discovered.
Academic authors were rarely involved in data analysis
and only two trials had a completely independent analysis.
When data analysis was performed jointly, the sponsor
seemed to take the leading role and, for some trials, the role
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tors to data analysis. We find it highly unlikely that many
academic authors with a clinical background actually parti-
cipated in the statistical analysis, as such analyses are time-
consuming and require statistical expertise. Based on our
previous study [10], such involvement might actually, again,
be limited to merely reading the clinical study report.
Data analysis done solely by the sponsor is problematic,
as independent analysis may yield different results [20]. In
some cases, the data were analysed by CROs, but they are
not independent. They are hired by the sponsor, they some-
times have financial interests in the sponsoring companies
[21,22], and - like for medical writers - if they do not do a
job that satisfies the sponsors’ marketing department, they
might go out of business. Furthermore, analysis by aca-
demic authors does not ensure independence, as such
authors often have financial ties to the industry [12]. Based
on their declarations in the paper, in the two trials with in-
dependent analysis, the academic authors were paid by the
companies for their contribution.
The sponsors’ dominating role in data analysis is not
only problematic in relation to selective reporting of posi-
tive outcomes and spin of the results [23,24], but also in re-
lation to stopping trials early. If the sponsor has access to
accumulating data, as was the case for at least 40 trials,
and is allowed to terminate the trials prematurely, this
could lead to overestimation of treatment effects [25] and
underestimation of harms [26].
Journal editors should consider whether independent
statistical analysis by academic authors should be a re-
quirement, as is the case for JAMA [7]. This policy has had
repercussions, as fewer industry-sponsored trials have been
published [27]. Such policies might therefore be difficult to
implement, as they will likely result in loss of revenue from
reprint sales of industry trials [2]. However, this only rein-
forces the need for independent analyses. Lastly, journals
should require copies of protocols and any additional
agreements to ensure that access to the data was planned
before the trial started. Journals should allocate editorial
resources to ensure that what appears in publications cor-
responds to statements written in protocols, which was not
always the case in our study. Such protocols should be
written in accordance with evidence-based standards such
as the upcoming SPIRIT guidelines [28] and should contain
detailed information on authors’ access to data. To ensure
that such declarations are more than window dressing
[10], journal editors might also consider asking for the raw
data as a condition for publication, like Science and the Na-
ture journals require [23] and preferably make such data
available at public websites.
Conclusions
The sponsors are usually involved in the analysis and
reporting of the results in industry-sponsored trials, buttheir exact role is not always clear from the published
papers. Even for fully industry-funded trials that appear to
have been conducted independently, the sponsors are also
sometimes explicitly involved in the reporting of results.
Journals should require more transparent reporting of the
sponsors’ role in crucial elements such as data processing,
statistical analysis and writing of the manuscript and should
consider requiring access to trial protocols, independent
data analysis and submission of the raw data.
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